{'fraction_non_alphanumeric': 0.0167973124300112, 'fraction_numerical': 0.0, 'mean_word_length': 5.04054054054054, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Blood‐based test to predict future risk of developing liver cancer

R esearchers have identified a blood-based test to predict the future risk of hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD). The test is useful in targeting intensive screening more accurately for liver disease to those at high risk and to reduce unnecessary screening for those at low risk by stratifying the risk between the patient groups. Reducing unnecessary screening is particularly important in under-resourced countries. Improving screening for HCC in patients with NAFLD is critical given the rapid rise in HCC incidence and mortality, as well as the shift from viral hepatitis as a major cause of HCC to NAFLD as a leading cause of liver disease. This places patients with NAFLD (particularly those who progress to cirrhosis) potentially at a high risk of developing HCC.